SITE CENTERS CORP
SITCNYSETrading Snapshot
- Day Range
- $3.77 – $3.83
- 52-Week Range
- $2.80 – $8.91
- Volume (shares)
- 3,705,859
- Avg Volume (shares)
- —
- Shares Outstanding
- 52.5M
- Next Earnings
- 2026-11-03
Fundamentals Snapshot
- Annual Revenue
- $123M
- Last Q Revenue
- $11M
- P/E Ratio
- 1.5
- P/S Ratio
- 2.8x
- EPS (TTM)
- $2.44
- Dividend Yield
- 179.48%
- Dilution (1yr)
- +0.0%
SITE CENTERS CORP
SITC
StockOtter · stockotter.spaceAbout SITE CENTERS CORP
SITE Centers specializes in the ownership and management of open-air retail complexes, curating an engaging shopping atmosphere and a desirable selection of stores for both its retail tenants and their customers. As a self-governing Real Estate Investment Trust (REIT), the company operates as a fully integrated real estate enterprise, managing all aspects of its operations internally. Its shares are publicly available on the New York Stock Exchange under the ticker symbol SITC.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve d
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting
Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional preclinical poster presentati
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company'
Pine Tree Acquires Sponsor Interest in a 10-Property, $644M Shopping Center Portfolio
CHICAGO, Oct. 20, 2026 /PRNewswire/ -- Pine Tree, a national owner and operator of open-air shopping centers, announced that it has acquired sponsor interest in a 10-property portfolio recently appraised at $644 million
SITE Centers Announces Sale of DTP Interests and Special Common Distribution
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of DTP Interests and Special Common Distribution.
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:AP